Capricor Therapeutics, Inc. (CAPR)
NASDAQ: CAPR · Real-Time Price · USD
34.70
+0.11 (0.32%)
At close: Apr 17, 2026, 4:00 PM EDT
34.42
-0.28 (-0.81%)
After-hours: Apr 17, 2026, 7:34 PM EDT
Capricor Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
231
Market Cap
2.01B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 22.27M | -2.91M | -11.55% |
| Dec 31, 2023 | 25.18M | 22.63M | 886.81% |
| Dec 31, 2022 | 2.55M | 2.31M | 941.85% |
| Dec 31, 2021 | 244.90K | -65.35K | -21.06% |
| Dec 31, 2020 | 310.25K | -694.78K | -69.13% |
| Dec 31, 2019 | 1.01M | -666.33K | -39.87% |
| Dec 31, 2018 | 1.67M | -994.98K | -37.32% |
| Dec 31, 2017 | 2.67M | -1.33M | -33.32% |
| Dec 31, 2016 | 4.00M | -1.52M | -27.53% |
| Dec 31, 2015 | 5.52M | 730.95K | 15.27% |
| Dec 31, 2014 | 4.79M | 4.28M | 851.19% |
| Dec 31, 2013 | 503.23K | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | 1.35M | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Galapagos NV | 1.31B |
| Aurinia Pharmaceuticals | 283.06M |
| AnaptysBio | 234.60M |
| Zymeworks | 105.97M |
| Recursion Pharmaceuticals | 74.68M |
| Mesoblast | 65.38M |
| Agios Pharmaceuticals | 54.03M |
CAPR News
- 5 weeks ago - Capricor Therapeutics Stock Slides As Q4 Earnings Miss Estimates - Benzinga
- 5 weeks ago - Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 5 weeks ago - Capricor Therapeutics Announces Late-Breaking HOPE-3 Data at the 2026 MDA Conference Demonstrating Significant Functional Benefits of Deramiocel for Duchenne Muscular Dystrophy - GlobeNewsWire
- 5 weeks ago - Capricor Therapeutics Stock Jumps As FDA Resumes Deramiocel Review - Benzinga
- 5 weeks ago - Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA - GlobeNewsWire
- 5 weeks ago - What's Going On With Moderna, Capricor, Other Biotech Stocks On Monday? - Benzinga
- 4 months ago - Capricor Therapeutics Announces Proposed Public Offering of Common Stock - GlobeNewsWire
- 4 months ago - Capricor Stock Soars, Shkreli Is Short: Here's What Pharma Bro Had To Say - Benzinga